January 23, 2013 7:33 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
pSivida Corp. (NASDAQ: PSDV), a leader in developing sustained release,drug delivery products for treatment of back-of-the-eye diseases, announcedtoday that the United Kingdom's National Institute for Health and ClinicalExcellence (NICE) has published final guidance indicating that ILUVIEN^® isnot cost effective for the treatment of chronic diabetic macular edema (DME)considered insufficiently responsive to available therapies. This finalguidance is consistent with the final draft guidance issued on November 29,2012.pSivida's licensee for ILUVIEN for DME, Alimera Sciences, Inc., reported thatit has chosen to pursue a Patient Access Scheme (PAS) for ILUVIEN for DME thatis intended to allow treatment decisions to be based on patient need, ratherthan cost. Alimera further reported that the PAS is currently under review bythe Patient Access Schemes Liaison Unit (PASLU) at NICE and that, if approvedby the Department of Health, the PAS will be available to the AppraisalCommittee for review and consideration. Alimera stated its belief that the PAScould be considered under NICE's rapid review facility should the PAS beaccepted.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.